411 related articles for article (PubMed ID: 11900310)
21. Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis.
Kamal MA; Qu X; Yu QS; Tweedie D; Holloway HW; Li Y; Tan Y; Greig NH
J Neural Transm (Vienna); 2008 Jun; 115(6):889-98. PubMed ID: 18235987
[TBL] [Abstract][Full Text] [Related]
22. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
Mazumder MK; Choudhury S
Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
[TBL] [Abstract][Full Text] [Related]
23. Acetylcholinesterase and butyrylcholinesterase inhibitory activities of antioxidant peptides obtained from enzymatic pea protein hydrolysates and their ultrafiltration peptide fractions.
Asen ND; Aluko RE
J Food Biochem; 2022 Nov; 46(11):e14289. PubMed ID: 35758753
[TBL] [Abstract][Full Text] [Related]
24. Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment.
Adeowo FY; Oyetunji TP; Ejalonibu MA; Ndagi U; Kumalo HM; Lawal MM
Chem Biodivers; 2021 Nov; 18(11):e2100361. PubMed ID: 34547176
[TBL] [Abstract][Full Text] [Related]
25. A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.
Nordberg A; Ballard C; Bullock R; Darreh-Shori T; Somogyi M
Prim Care Companion CNS Disord; 2013; 15(2):. PubMed ID: 23930233
[TBL] [Abstract][Full Text] [Related]
26. Cholinesterase inhibitors: new roles and therapeutic alternatives.
Giacobini E
Pharmacol Res; 2004 Oct; 50(4):433-40. PubMed ID: 15304240
[TBL] [Abstract][Full Text] [Related]
27. A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.
Andrisano V; Naldi M; De Simone A; Bartolini M
Expert Opin Ther Pat; 2018 Jun; 28(6):455-465. PubMed ID: 29757691
[TBL] [Abstract][Full Text] [Related]
28. The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase.
Petzer A; Harvey BH; Petzer JP
Toxicol Appl Pharmacol; 2014 Feb; 274(3):488-93. PubMed ID: 24161345
[TBL] [Abstract][Full Text] [Related]
29. Dual inhibition of acetylcholinesterase and butyrylcholinesterase enzymes by allicin.
Kumar S
Indian J Pharmacol; 2015; 47(4):444-6. PubMed ID: 26288480
[TBL] [Abstract][Full Text] [Related]
30. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
[TBL] [Abstract][Full Text] [Related]
31. New cholinesterase inhibitors for Alzheimer's disease: Structure activity relationship, kinetics and molecular docking studies of 1-butanoyl-3-arylthiourea derivatives.
Larik FA; Shah MS; Saeed A; Shah HS; Channar PA; Bolte M; Iqbal J
Int J Biol Macromol; 2018 Sep; 116():144-150. PubMed ID: 29729344
[TBL] [Abstract][Full Text] [Related]
32. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Bullock R
Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB
ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948
[TBL] [Abstract][Full Text] [Related]
34. Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning as Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase.
Wang DM; Feng B; Fu H; Liu AL; Wang L; Du GH; Wu S
Molecules; 2017 Jan; 22(1):. PubMed ID: 28117700
[TBL] [Abstract][Full Text] [Related]
35. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
36. Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimer's Disease.
Okello EJ; Mather J
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32326457
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of indole derivatives as Alzheimer inhibitors and their molecular docking study.
Homoud ZA; Taha M; Rahim F; Iqbal N; Nawaz M; Farooq RK; Wadood A; Alomari M; Islam I; Algheribe S; Rehman AU; Khan KM; Uddin N
J Biomol Struct Dyn; 2023 Nov; 41(19):9865-9878. PubMed ID: 36404604
[TBL] [Abstract][Full Text] [Related]
38. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.
Poirier J
Int J Clin Pract Suppl; 2002 Jun; (127):6-19. PubMed ID: 12139368
[TBL] [Abstract][Full Text] [Related]
39. Acetylcholinesterase and butyrylcholinesterase inhibition by nectriapyrone and tryptophol isolated from endophytic fungus
Dos Santos R; Morais-Urano RP; Marçal RM; Silva GH; Santos MFC
Nat Prod Res; 2022 Aug; 36(16):4153-4158. PubMed ID: 34498969
[TBL] [Abstract][Full Text] [Related]
40. [Cholinesterases and their importance in the etiology, diagnosis and therapy of Alzheimer's disease].
Patocka J; Strunecká A; Rípová D
Cesk Fysiol; 2001 Feb; 50(1):4-10. PubMed ID: 11268561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
